SENA BIANNUAL MEETING

The changing treatment landscape in motor neuron disease

Dr Liu is a consultant neurologist at the Royal Free London NHS Foundation Trust. She treats patients with a wide range of neurological conditions and medically unexplained symptoms.

She offers a specialist epilepsy service covering all aspects of seizure management from newly diagnosed epilepsy to complex and difficult to control epilepsy. She emphasises a holistic approach to managing epilepsy, concentrating not only on medication but mood, memory and social wellbeing.

Dr Liu is the trust lead for functional neurological disorders and has established a clinical service for patients with dissociative seizures.

She completed her medical training at Guy's and St Thomas' Hospital and obtained a first class BSc Degree in psychology from University College London. She conducted her postgraduate medical training at the National Hospital for Neurology and Neurosurgery, Queen Square and the Royal Free Hospital, London.

She developed her epilepsy skills at The Epilepsy Society, Chalfont and Queen Square.

Neuro-Hepatology

Advances in diagnosis and treatment of amyloid

Professor Julian Gillmore undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis.

He was appointed centre head at UCL's centre for amyloidosis in 2019 and is research lead at the UK national amyloidosis centre.

Dr. Gillmore was the first scientist to systematically highlight the relationship between the abundance of amyloid fibril precursor proteins, the course of amyloid deposits and the clinical outcome in several different forms of Amyloidosis.

Update on spasticity management

Dr Donnelly completed her neurology training at King's College Hospital, Guys and St Thomas' and the National Hospital for Neurology and Neurosurgery.

She completed a fellowship in spasticity and neurorehabilitation at the National Hospital for Neurology and Neurosurgery and has been the consultant for the Royal Free London neurological rehabilitation centre since 2019. Her specialist interests are neurorehabilitation and complex spasticity management.

Development of new approaches to disease management in Parkinson's

Professor Anthony Schapira was appointed in 1990 as chairman of the University Department of Clinical Neurosciences at the UCL Queen Square Institute of Neurology, and professor of neurology at the National Hospital for Neurology and Neurosurgery, UCLH and the Royal Free London Hospital, London, UK. He is currently head of the department of clinical and movement neurosciences at UCL Queen Square Institute of Neurology. He is a member of the board of the Oxford University Hospitals Board. He was appointed to the NHS Reconfiguration Board in 2019.

Professor Schapira's research interests include the molecular and clinical aspects of neurodegenerative diseases, with special emphasis on Parkinson disease and other movement disorders. He has over 450 peer-reviewed publications with more than 35 in Nature or Lancet series journals, and has edited over 15 books on various aspects of neurology including the textbook Neurology and Clinical Neuroscience. His H-index is 97 (Thomson, WoS), 121 (Google Scholar) and he has 16 Citation Classics (>400 citations). He is on the 2018 list of the world's most highly cited researchers (Clarivate).

Professor Schapira is the recipient of the Harveian Medal, the Royal College of Physicians Clinical Science Prize, the European Prize for Clinical Science, the 1999 Opprecht Foundation Award and the Duchenne Prize. He was elected a fellow of the Academy of Medical Sciences in 1999. He was appointed a senior investigator at the National Institutes of Health Research in 2012. He was editor-in-chief of the European Journal 2006-2019.

Early diagnosis of Parkinson's and Parkinson's Plus conditions

Huw Morris is consultant neurologist and professor of clinical neuroscience at the Royal Free Hospital, National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology.

His main clinical and research interests are in movement disorders and neurogenetics, particularly early onset, genetic and familial Parkinson's disease and atypical Parkinsonian disorders such as progressive supranuclear palsy, cortico-basal degneration and fronto-temporal dementia with Parkinsonism.

His clinical and research training took place at the National Hospital, Queen Square, the Mayo Clinic and the Western Pacific island of Guam. He sees patients on an NHS and research basis. His research is funded by Parkinson's UK, the Medical Research Council, the PSP Association and the Motor Neuron Disease Association.

Novel Treatments in Alzheimer's disease

Jonathan works at the Royal Free London NHS Foundation Trust where he is the Clinical Director for Neurosciences and is a member of the NCL STP Neurology Group.

He trained at Imperial College in London. He undertook clinical training in a number of London teaching hospitals, including a period as a clinical research fellow at the National Hospital for Neurology and Neurosurgery.

Jonathan has expertise across general neurology with a specialist interest in dementia and cognitive disorders. He developed the Cognitive Disorders Service at the Royal Free and was part of the London memory Network Steering Group.

He enjoys teaching both within medicine and allied disciplines. He co-authored the book Neurology for MRCP and regularly teaches for both University College London and Birkbeck University.

Debate: This house believes that consultant neurologists should be managing acute neurology in the emergency department

Dr Ben Turner is a highly experienced Consultant Neurologist. He was appointed to St Bartholomew's and The Royal London NHS Hospitals in 2003. An Honorary Senior Lecturer for his research work and publications in Multiple Sclerosis and other Neurological Conditions, such as Headache and Dizziness.

Dr Turner is also actively involved in research into Multiple Sclerosis, particularly clinical research into new therapies, and has over 20 years clinical trial experience. He is Chief UK and Principal Investigator for several phase III clinical treatment trials and leads the HSCT stem cell therapy programs for MS at Bart's Health NHS Trust. Through this work Dr Turner has an extensive knowledge and experience in the full range of disease modifying therapies available to MS patients.

As an NHS consultant in a busy London Teaching Hospital, Dr Turner has two decades of experience in the full range of neurological conditions, caring for patients suffering from daily complaints such as headache and dizziness as well as life threatening conditions such as TB meningitis.

Dr Turner is Clinical and Educational Lead of Neurology for Barts Health NHS Trust, As Clinical lead Dr Turner manages the Neurology department and helps develop its role in a large London Teaching Hospital, providing for one the most ethnically rich but economically poor areas of the UK.

Debate: This house believes that consultant neurologists should be managing acute neurology in the emergency department

Adrian Wills was a Neurologist but found the concept of left brain supplying right body too intellectually challenging so currently spends his spare time seeing patients with coughs, tummy ache and nasty rashes. A late life crisis has led him to adopt an Arcadian lifestyle. He keeps bees (current honey production zero) and is a fully fledged falconer but denies all accusations of being "under the thumb".

The pandemic and the post-pandemic future of the NHS

Stephen Powis is the National Medical Director of NHS England and Professor of Renal Medicine at University College London.

Previously he was Medical Director (and latterly Group Chief Medical Officer) of the Royal Free London NHS Foundation Trust from 2006 to 2018. Professor Powis was also a member of the governing body of Merton Clinical Commissioning Group for five years and a Director of Healthcare Services Laboratories LLP.

He is a past Chairman of the Association of UK Universities (AUKUH) Medical Directors Group and has been a member of numerous national committees and working groups, including the Department of Health Strategic Education Funding Expert Group. He is a past non-executive director of the North Middlesex University Hospital NHS Trust, including a period of eight months as acting chairman.

He is a past chairman of the Joint Royal Colleges of Physicians Training Board (JRCPTB) Specialty Advisory Committee (SAC) for Renal Medicine and a former board member of Medical Education England. He was Director of Postgraduate Medical and Dental Education for UCLPartners from 2010-13. He is a past treasurer and trustee of the British Transplantation Society and a former member of the UK Transplant Kidney Pancreas Advisory Group.

He has also served as a member of the Renal Association Executive Committee. He was Editor of the journal Nephron Clinical Practice from 2003 to 2008. In 2017 he became the inaugural Editor-in-Chief of the journal BMJ Leader. He has been a trustee of several charities, including the Royal Free Charity and the Healthcare Management Trust.

Is it Lymphoma?

Luke is a consultant neuroradiologist at Imperial College Healthcare NHS Trust and honorary clinical research fellow under the Division of Surgery and Cancer.

His main research interests are neuro-oncology and vascular imaging and he is co-lead of the translational brain tumour research group at Imperial College. Within neuro-oncology, Luke is particularly interested in the application of advanced, multiparametric intraoperative ultrasound in guiding brain tumour resection.

Judgement Day

Dr Kennedy qualified from Charing Cross Medical School in 1985 and subsequently trained as a neurologist at Atkinson Morley Hospital. His research used functional imaging and was carried out at the MRC Cyclotron Unit, Hammersmith Hospital and the Dementia Research Group, Institute of Neurology, Queen Square.

He was appointed to the consultant staff at The Chelsea and Westminster and Charing Cross Hospitals in 1997 and is the clinical lead for neurology at Chelsea and Westminster Hospital.

He has areas of interest in all aspects of neurology, but particularly Alzheimer's disease, dementia, Parkinson's disease, and stroke.

About Us

This website is owned and operated by the South of England Neurosciences Association (“SENA“, “we“, “our” or “us”).

Terms of Use

The material contained within the website includes copyrighted animations, photographs, images, videos, text, music, and sounds (collectively, the "Content"). The "Site" refers to the website, its content, design, organisation, layout and functions.

Governing Law

SENA is a Charitable Incorporated Organisation (CIO) registered in England & Wales [Charity No.1198001]. The terms and conditions and the use of the Site shall be governed and construed in accordance with the laws of England and Wales and the parties hereto submit to the exclusive jurisdiction of the English courts in all disputes arising out of or relating to the Site and/or any transactions made on the Site, or these Terms of Use. However, some of the information in the pages contained in this website may not be accessed from certain jurisdictions and no representation or warranty is made as to whether the information available in this website complies with the regulatory regime of countries other than the United Kingdom.

Use of this Site

Your access to and use of this Site and/or the media on which it is stored is subject to the following terms and conditions and all applicable laws. By accessing and browsing this Site, you accept, without limitation or qualification, these Terms of Use and acknowledge that any prior agreements, written or oral, between you and SENA are superseded and of no force or effect. If these Terms of Use are not accepted in full, the use of this Site must be terminated immediately.

Furthermore, your use of this Site warrants to Us that you will not use the Site, the Content or any part thereof for any purpose that is in contravention of any applicable law or regulation or in a manner that will infringe the copyright, trademarks, service marks or other intellectual property rights of third parties or violate the privacy, publicity or other personal rights of others or in any defamatory, obscene, threatening, abusive or hateful manner.

You agree to use this Site only for lawful purposes and in a manner which does not infringe the rights or restrict or inhibit the use and enjoyment of the Site by any third party.

Images and Proprietary Rights

All logos, trademarks, copyright, database rights and other intellectual property rights in the materials on this Site are owned either directly by Us, by our Content suppliers or by Our licensors. All other company, brand and product names and logos are trademarks or registered trademarks of their respective owners, should be treated as such, and may be registered in various jurisdictions.

Nothing contained herein shall be construed as conferring any licence or transfer of title or intellectual property rights to you by Us or any third party.

Some documents, photos and videos have been published on this Site with the permission of the relevant copyright owners (who are not SENA). All rights are reserved on these documents and permission to copy them must be requested from the copyright owners (the sources are indicated within these documents/photographs).

Images used within the Site may feature images of people, animals and places. Models may have been used in some of the pictures and no inference should be made as to their past, present or future relationship or communication with SENA, its employees, directors, contractors or other third party.

Furthermore, we make no representation or warranty as to your right to use any individual's name, likeness, and/or image appearing in the Content without first obtaining appropriate rights from such individual. You may not use photos or images of people or identifiable entities in any manner that suggests the endorsement or association of any product or service or in connection with any pornographic or immoral materials.

You shall not copy, reproduce, distribute, transmit, broadcast, display, sell, license, or otherwise exploit any Content for any other purposes without the prior written consent of SENA or the respective licensors of the Content.

Privacy Policy

We are committed to respecting and keeping safe any personal data you share with us. We aim to be clear when we collect your data and not use it in a way that you wouldn't expect. In particular, we want you to know that we are not in the business of selling, renting or trading email lists with other companies and businesses for marketing purposes.

Personal data is any information that can be used to identify you. For example, it can include information such as your name, date of birth, email address, postal address, telephone number and credit/debit card details, as well as information relating to your health or personal circumstances. This website does not request or collect personal information about you in any way.

If you contact us by e-mail or telephone, any information you provide may be retained by us for the purposes of performing a contract and conducting business as usual. We will not share or make public any information provided by you without your prior permission unless it can be shown that such information is already within the public domain, it is already in our possession prior to you contacting us, or we are required to do so by regulatory bodies or goverment agences with the approrpiate legal authority.

Cookies

Cookies are small pieces of text stored as a file on the computer's hard drive. They are used by your browser and by most websites to help personalise or improve your web experience. They are not computer programmes, and they cannot be executed as code. They cannot be used to disseminate viruses or access the hard drives - a cookie cannot read other information saved on the hard drive, or get a user's personal data. They only contain and transfer to the web server as much information as the users themselves have disclosed to a certain website.

The Help menu on the menu bar of most browsers will tell you how to prevent your browser from accepting new cookies, how to have the browser notify you when you receive a new cookie and how to disable cookies altogether. Additionally, you can disable or delete similar data used by browser add-ons, such as Flash cookies, by changing the add-on's settings or visiting the website of its manufacturer. You can find more information about deleting and controlling cookies from the AboutCookies.org website.

Changes to this Terms of Use and Privacy Policy

We may change this Terms of Use and Privacy Policy from time to time by updating this page. Please check this page periodically to ensure that you are happy with any changes. If you have any questions, comments or suggestions, you can contact us by email at [email protected].